Treatment of Kocuria kristinae Infection
Vancomycin is the recommended first-line empirical treatment for Kocuria kristinae infections, administered intravenously until antimicrobial susceptibility results are available 1, 2.
Initial Empirical Therapy
Start with vancomycin as the primary agent because:
- K. kristinae shows the lowest resistance rates to vancomycin (only 7% resistance) 1
- A systematic review of invasive K. kristinae infections demonstrated nearly universal treatment effectiveness with vancomycin-based regimens, with only one death reported 2
- This approach is supported across multiple case series and should be initiated immediately upon identification of this organism 1, 2
Consider combination therapy by adding a second agent based on the infection site and severity:
- For catheter-related bloodstream infections: vancomycin alone may suffice 3
- For severe infections (empyema, endocarditis): add piperacillin-tazobactam or a carbapenem 4, 5
- For device-related infections: catheter or device removal is essential alongside antibiotics 3, 6
Alternative Agents Based on Susceptibility
Once susceptibility testing returns, consider de-escalation or alternative agents with high susceptibility rates:
- Linezolid (alternative if vancomycin intolerance develops) 7, 8
- Cephalosporins (39.6% usage rate in reported cases) 1
- Quinolones (levofloxacin effective in empyema cases) 5
- Meropenem (used successfully in catheter-related infections with pulmonary involvement) 4
- Tetracyclines (only 6.7% resistance) 1
Duration and Route
- Initial IV therapy for 7-14 days minimum 3
- For uncomplicated bacteremia: 14 days total may be adequate 3
- For endocarditis: minimum 4-6 weeks (following standard IE guidelines) 8
- For device-related infections: 14 days after device removal 3
Critical Management Points
Source control is mandatory:
- Remove infected central venous catheters, ports, or other devices 3, 6
- Drain abscesses or empyema 5
- Consider valve replacement for prosthetic valve endocarditis 8
High-risk populations requiring vigilance:
- Immunocompromised patients
- Those with long-term central venous access 4, 3
- Patients with short bowel syndrome or decreased bowel immunity 3
- Prosthetic valve recipients 8
Common Pitfalls
- Do not delay treatment waiting for species identification—K. kristinae grows readily in blood cultures but may be dismissed as a contaminant
- Do not assume contamination when isolated from blood cultures, especially in patients with indwelling devices 1
- Do not use monotherapy for serious infections like endocarditis or empyema—combination therapy improves outcomes 4, 5
- Do not forget to assess for metastatic complications including pulmonary nodules, endocarditis, or septic arthritis in bacteremic patients 4, 7
The infection outcome depends primarily on the infection type, with endocarditis carrying higher mortality and endophthalmitis associated with poor visual outcomes 1.